PRDM16::SKI is a predictor of aberrant expression of the short variant of PRDM16 in pediatric acute myeloid leukemia
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
The RNA-sequencing data from the Japanese Children’s Cancer Group (JCCG)’s AML-05 study was re-analyzed to clarify the mechanisms related to high PRDM16 expressions, which is independently associated with adverse outcomes. Results showed that 19 of 139 patients presented with out-of-frame PRDM16::SKI fusions. Thus, the gene expression levels of PRDM16::SKI in 369 and 329 patients from the AML-05 and AML-12 studies, respectively, were measured. In total, 119 (32%) of 369 patients in the AML-05 study and 58 (18%) of 329 patients in the AML-12 study presented with an aberrant expression of PRDM16::SKI . This fusion was a 48-base-pair product that immediately formed a stop codon on the SKI side. The introduction of this product in mice did not cause AML. Intriguingly, none of the patients presented with SKI::PRDM16 , which is reciprocal. Moreover, partner fusion genes were not detected in front of truncated PRDM16 , indicating that a short form of PRDM16 , which lacked exon 1, existed by itself. Patients with high PRDM16::SKI expression had significantly worse overall survival and event-free survival than those with a low PRDM16 expression. The cleavage between exons 1 and 2 of PRDM16 induces aberrant PRDM16 expression, and a strong associations was observed between PRDM16::SKI and PRDM16 expression.